Drug Profile
Coltuximab ravtansine
Alternative Names: Anti-CD19-DM4 immunoconjugate SAR3419; huB4-DM4; Maytansin-loaded anti-CD19 mAb; SAR-3419Latest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
- Mechanism of Action CD19 antigen inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Diffuse large B cell lymphoma
Highest Development Phases
- Phase II Diffuse large B cell lymphoma
- Discontinued Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 21 Aug 2019 Coltuximab ravtansine is still in phase II for Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in Austria, Belgium, Czech Republic, France, Israel, Italy, Norway, Poland, Spain, Sweden, Turkey, USA and United Kingdom
- 30 Sep 2016 Coltuximab ravtansine is available for licensing as of 30 Sep 2016. http://www.immunogen.com/